CanCell Therapeutics

Advesya (formerly CanCell Therapeutics) is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and autoimmune diseases. The company specializes in targeting the Interleukin-1 receptor accessory protein (IL-1RAP), a unique antigen overexpressed in various hematological and solid malignancies as well as chronic inflammatory conditions. Its lead candidate, CCTx-001, is a first-in-class autologous CAR-T cell therapy currently in Phase 1/2 clinical trials for relapsed or refractory acute myeloid leukemia (AML). Additionally, Advesya is advancing ADV-101, an antibody-drug conjugate (ADC) targeting IL-1RAP for both hematological and solid tumors. Spun off from the French Blood Institute (EFS) and INSERM, the company leverages decades of academic research to provide precision treatments that specifically eliminate diseased cells while sparing healthy tissue.